One Watertown, Mass.-based biotech is working to capitalize on growing momentum for cell and gene therapies — and it seems to have found its opening.
The company is working on a technology that will squeeze cells to open up tiny pores in their membranes to deliver gene therapies or medicines straight into the cell. And SQZ has had a busy fall. It closed a $72 million series C fundraising round in August. Even more recently, the company extended a partnership with Roche (RHHBY) that could bring in more than $1.3 billion, if SQZ and Roche can get some products to market.